Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688796'
s Net Margin % Range Over the Past 10 Years
Min: -168.84 Med: -83.09 Max: 12.59
Current: 12.59
SHSE:688796's Net Margin % is ranked better than 82.06% of 942
companies
in the Biotechnology industry
Industry Median: -88.295
vs SHSE:688796: 12.59
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biocytogen Pharmaceuticals (Beijing) Co Net Margin % Related Terms
Biocytogen Pharmaceuticals (Beijing) Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co Net Margin % Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
SHSE:688796 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co Net Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a Net Margin % of 16.52% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #169 out of 942 companies in the Biotechnology industry, placing it in the top 17.9%.
Is Biocytogen Pharmaceuticals (Beijing) Co's Net Margin % too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Net Margin % is 16.52%. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #169 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #169 out of 942 companies for Net Margin %. This places Biocytogen Pharmaceuticals (Beijing) Co in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Net Margin % is 16.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥45.10, compared to a current price of ¥120.78 — trading 167.8% above its estimated fair value. The current Net Margin % is 16.52%. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current Net Margin % is 16.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of ¥120.78 is trading 167.8% above its estimated GF Value™ of ¥45.10.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for SHSE:688796:
Net Margin %: 16.52%
GF Value™: ¥45.10 vs. price of ¥120.78 (167.8% above fair value)
No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
45GF Score
Get the complete analysis for SHSE:688796
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688796 has been successfully added to your 
